An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention

Active, not recruitingOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

October 31, 2024

Conditions
Migraine Disorders
Interventions
DRUG

DaxibotulinumtoxinA

"Patients enrolled who meet eligibility will receive a total of 344 units of DAXI Injections in divided doses over 19 landmarks, including the face, head and shoulders, as identified per the EEG paradigm, at visit 2.~Follow-up visits via combination of phone and in office will occur at V3, week 8 thru V9, week 24."

Trial Locations (2)

90067

The Los Angeles Headache Center, Los Angeles

06905

New England Institute For Clinical Research, Stamford

All Listed Sponsors
collaborator

The Los Angeles Headache Center

UNKNOWN

collaborator

Revance Therapeutics, Inc.

INDUSTRY

lead

Ki Health Partners. LLC

INDUSTRY

NCT06154070 - An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention | Biotech Hunter | Biotech Hunter